Practical report of use for discrimination between hepatocellular carcinoma (HCC) and hemodynamic abnormalities: Discriminatory diagnosis of HCC versus hemodynamic abnormalities

Graduate School of Medicine, Yamaguchi University  
Dept. of Radiology  
Drs. Masahiro Tanabe, Takeshi Fujita, Naofumi Matsunaga

DATE : 2021

Discriminatory diagnosis of HCC versus hemodynamic abnormalities

Discriminatory diagnosis of HCC versus hemodynamic abnormalities

Patient’s background and objectives of magnetic resonance imaging (MRI)

Male, 70s.
The patient had chronic hepatitis C, with elevated PIVKA-II (7,900 mAU/mL), and ultrasonography showed a mass approxi-mately 2 cm in diameter in S8 of the liver.
Computed tomography (CT) and MRI were performed to determine the HCC stage. The interval between CT and MRI was 18 days.

a) Arterial phase

a) Arterial phase

b) Late phase

b) Late phase

Multidetector CT

In the arterial phase (a), a dark-stained mass approximately 2 cm in diameter was found in S8 of the liver (red arrow), and a wedge-shaped, dark-stained region was found in the periphery of S7/8 of the liver (blue arrow). In late stage (b), the mass in S8 of the liver showed contrast enhancement wash-out, and HCC was diagnosed. Hemodynamic abnormality was suspected, because wash-out was not found in the peripheral part of S7/8 of the liver. However, because the option of surgery was being considered, detailed examination was judged to be necessary.

c) Pre-contrast, T1-weighted image

c) Pre-contrast, T1-weighted image

d) T2-weighted, fast-spin echo image

d) T2-weighted, fast-spin echo image

MRI

The mass (red arrow) in S8 of the liver gave a low signal in pre-contrast, T1-weighted imaging (c). In addition, in T2-weighted imaging (d) the mass gave a higher signal than the surrounding hepatic parenchyma, and its interior was somewhat heterogeneous.

e) Arterial phase

e) Arterial phase

f) Portal phase

f) Portal phase

g) Late phase

g) Late phase

h) Hepatobiliary phase

h) Hepatobiliary phase

Gadoxetate disodium(Gd-EOB-DTPA) contrast

In the Gadoxetate disodium(Gd-EOB-DTPA) contrast MRI arterial phase (e), the mass in S8 of the liver (red arrow) was stained even more intensely than the surrounding hepatic parenchyma, and it showed wash-out from the portal phase (f) to the late phase (g). In the hepatobiliary phase (h), the signal decreased markedly, and the border with the surrounding tissues became distinct. On the other hand, whereas a wedge-shaped, dark-stained region (blue arrow) was found in the periphery of S7/8 of the liver in the arterial phase (e), in the hepatobiliary phase (h) the signal was approximately the same as in the surrounding hepatic parenchyma, and hemodynamic abnormality was therefore diagnosed.

Summary

After the above, by means of surgery the tumor in S8 of the liver was diagnosed as moderately differentiated HCC. 
No mass was found in the periphery of S7/8 of the liver by intraoperative ultrasonography. 
It is possible to thoroughly assess hemodynamics by means of dynamic examination after Gadoxetate disodium(Gd-EOB-DTPA) administration. Typical HCC is characterized by early-phase dark staining and late-phase wash-out, and these signs were found with the present patient. 
In addition, inclusion of the hepatobiliary phase resulted in visualization of the lesion, giving a distinct low signal, and this is expected to lead to increased detection effectiveness. On other hand, pseudolesions such as hemodynamic abnormalities present problems for diagnosis of HCC. Uptake of Gadoxetate disodium(Gd-EOB-DTPA) by hepatocytes makes it possible to rule out the pseudolesions that present problems for diagnosis on the basis of hemodynamics alone.

Precautions relating to administration

Administration to elderly patients   
Elderly patients generally show depressed physiological function, so administration must be performed with care, and with sufficient monitoring of the patient’s condition.

  • * The case introduced is just one clinical case, so the results are not the same as for all cases.
  • * Please refer to the Package Insert for the effects and indications, dosage and administration method, and warnings, contraindications, and other precautions with use.

References

  1. InchingoloR, FalettiR, GrazioliL, TricaricoE, GattiM, PecorelliA, et al. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol. 2018;10(7):462–73.
  2. TanCH, ChouS, InmuttoN, MaK, ShengR, ShiY, et al. Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting. Korean J Radiol. 2022;23(7):697.
  3. HigakiA, ItoK, TamadaT, TerukiS, YamamotoA, HigashiH, et al. High-risk nodules detected in the hepatobiliary phase of Gd-EOB-DTPA-enhanced mr imaging in cirrhosis or chronic hepatitis: Incidence and predictive factors for hypervascular transformation, preliminary results. J Magn Reson Imaging. 2013;37(6):1377–83.
  4. SuhCH, KimKW, PyoJ, LeeJ, KimSY, ParkSH. Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI: A systematic review and meta-analysis. Am J Roentgenol. 2017;209(4):781–9.
  5. ChoYK, KimJW, KimMY, ChoHJ. Non-hypervascular hypointense nodules on hepatocyte phase gadoxetic acid-enhanced MR images: Transformation of MR hepatobiliary hypointense nodules into hypervascular hepatocellular carcinomas. Gut Liver. 2018;12(1):79–85.
  6. LeeDH, LeeJM, LeeJY, KimSH, KimJH, YoonJH, et al. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: Risk of HCC recurrence after radiofrequency ablation. J Hepatol. 2015 May;62(5):1122-30.
  7. ChiuN-C, SuC-W, LiuC-A, HuangY-H, ChiouY-Y. Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections. PLoS One. 2017;12(6).
  8. ToyodaH, KumadaT, TadaT, NiinomiT, ItoT, SoneY, et al. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol [Internet]. 2013;58(6):1174–80. Available from: http://dx.doi.org/10.1016/j.jhep.2013.01.030